Iressa Approval Would Set Bad Precedent For Oncology, Genta CEO Tells BIO

FDA's decision about AstraZeneca's pending oncologic Iressa will send a "strong message" to industry about whether the agency is serious about high approval standards for cancer drugs, Genta CEO Ray Warrell, MD, said Feb. 26 during the Biotechnology Industry Organization CEO and investor conference in New York